APO RESEARCH · REPORT
5-HT Receptor Antagonist
5-HT Receptor Antagonist refers to medicinal, supplement or research preparations identified by the named composition or biological target.
Product & engineering
Understand the product.
Identity, formulation, stock form, controls and documented use define the preparation; market categories and images do not establish approval, dosing or patient suitability.
What turns activity into demand
Distinguish equipment procurement, recurring materials and any related service within the selected study. Research use, educational use and clinical use have different acceptance requirements and should not be treated as one demand measure.
The commercial boundary
Separate research materials, devices and services within the selected edition. Approvals, labelled use and clinical acceptance need their own evidence; no medical suitability follows from this illustration.
Which supplied scope and interfaces define 5-HT Receptor Antagonist?
Identity, formulation, stock form, controls and documented use define the preparation; market categories and images do not establish approval, dosing or patient suitability.
Selected research
Industry Research
5-HT Receptor Antagonist Industry Research Report 2026
Market perspective
The global 5-HT Receptor Antagonist market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for 5-HT Receptor Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for 5-HT Receptor Antagonist is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for 5-HT Receptor Antagonist is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of 5-HT Receptor Antagonist include Teva, Johnson and Johnson, Novartis, Jiangsu Hausen Pharmaceutical Group, Zentiva, Vitoria Pharma, Torrent Pharmaceuticals, Shionogi Seiyaku and Sanofi Aventis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global 5-HT Receptor Antagonist market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
5-HT Receptor Antagonist Market by Company
Teva
Johnson and Johnson
Novartis
Jiangsu Hausen Pharmaceutical Group
Zentiva
Vitoria Pharma
Torrent Pharmaceuticals
Shionogi Seiyaku
Sanofi Aventis
Odyssey Pharmaceuticals
Nu Pharm
Nidda Healthcare Holding Gmbh
Neuraxpharm Arzneimittel
Famar
Aspen Pharmacare
Aristo Pharma
Apotex
Ahaan Healthcare
Advanz Pharma
Abz-Pharma
5-HT Receptor Antagonist Segment by Type
Agomelatine
Trimipramine
Other
5-HT Receptor Antagonist Segment by Application
Hospital
Clinic
Other
5-HT Receptor Antagonist Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global 5-HT Receptor Antagonist market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of 5-HT Receptor Antagonist and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of 5-HT Receptor Antagonist.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of 5-HT Receptor Antagonist manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of 5-HT Receptor Antagonist by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of 5-HT Receptor Antagonist in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Agomelatine
- Trimipramine
- Other
Applications
- Hospital
- Clinic
- Other
Companies covered
- Teva
- Johnson and Johnson
- Novartis
- Jiangsu Hausen Pharmaceutical Group
- Zentiva
- Vitoria Pharma
- Torrent Pharmaceuticals
- Shionogi Seiyaku
- Sanofi Aventis
- Odyssey Pharmaceuticals
- Nu Pharm
- Nidda Healthcare Holding Gmbh
- Neuraxpharm Arzneimittel
- Famar
- Aspen Pharmacare
- Aristo Pharma
- Apotex
- Ahaan Healthcare
- Advanz Pharma
- Abz-Pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global 5-HT Receptor Antagonist Market Size (2021-2032)
- 2.2.2 Global 5-HT Receptor Antagonist Sales (2021-2032)
- 2.2.3 Global 5-HT Receptor Antagonist Market Average Price (2021-2032)
- 2.3 5-HT Receptor Antagonist by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Agomelatine
- 2.3.3 Trimipramine
- 2.3.4 Other
- 2.4 5-HT Receptor Antagonist by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global 5-HT Receptor Antagonist Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global 5-HT Receptor Antagonist Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global 5-HT Receptor Antagonist Revenue of Manufacturers (2021-2026)
- 3.4 Global 5-HT Receptor Antagonist Average Price by Manufacturers (2021-2026)
- 3.5 Global 5-HT Receptor Antagonist Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of 5-HT Receptor Antagonist, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of 5-HT Receptor Antagonist, Product Type & Application
- 3.8 Global Manufacturers of 5-HT Receptor Antagonist, Established Date
- 3.9 Global 5-HT Receptor Antagonist Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva
- 4.1.1 Teva Company Information
- 4.1.2 Teva Business Overview
- 4.1.3 Teva 5-HT Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva 5-HT Receptor Antagonist Product Portfolio
- 4.1.5 Teva Recent Developments
- 4.2 Johnson and Johnson
- 4.2.1 Johnson and Johnson Company Information
- 4.2.2 Johnson and Johnson Business Overview
- 4.2.3 Johnson and Johnson 5-HT Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Johnson and Johnson 5-HT Receptor Antagonist Product Portfolio
- 4.2.5 Johnson and Johnson Recent Developments
- 4.3 Novartis
- 4.3.1 Novartis Company Information
- 4.3.2 Novartis Business Overview
- 4.3.3 Novartis 5-HT Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Novartis 5-HT Receptor Antagonist Product Portfolio
- 4.3.5 Novartis Recent Developments
- 4.4 Jiangsu Hausen Pharmaceutical Group
- 4.4.1 Jiangsu Hausen Pharmaceutical Group Company Information
- 4.4.2 Jiangsu Hausen Pharmaceutical Group Business Overview
- 4.4.3 Jiangsu Hausen Pharmaceutical Group 5-HT Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Jiangsu Hausen Pharmaceutical Group 5-HT Receptor Antagonist Product Portfolio
- 4.4.5 Jiangsu Hausen Pharmaceutical Group Recent Developments
- 4.5 Zentiva
- 4.5.1 Zentiva Company Information
- 4.5.2 Zentiva Business Overview
- 4.5.3 Zentiva 5-HT Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Zentiva 5-HT Receptor Antagonist Product Portfolio
- 4.5.5 Zentiva Recent Developments
- 4.6 Vitoria Pharma
- 4.6.1 Vitoria Pharma Company Information
- 4.6.2 Vitoria Pharma Business Overview
- 4.6.3 Vitoria Pharma 5-HT Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Vitoria Pharma 5-HT Receptor Antagonist Product Portfolio
- 4.6.5 Vitoria Pharma Recent Developments
- 4.7 Torrent Pharmaceuticals
- 4.7.1 Torrent Pharmaceuticals Company Information
- 4.7.2 Torrent Pharmaceuticals Business Overview
- 4.7.3 Torrent Pharmaceuticals 5-HT Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Torrent Pharmaceuticals 5-HT Receptor Antagonist Product Portfolio
- 4.7.5 Torrent Pharmaceuticals Recent Developments
- 4.8 Shionogi Seiyaku
- 4.8.1 Shionogi Seiyaku Company Information
- 4.8.2 Shionogi Seiyaku Business Overview
- 4.8.3 Shionogi Seiyaku 5-HT Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Shionogi Seiyaku 5-HT Receptor Antagonist Product Portfolio
- 4.8.5 Shionogi Seiyaku Recent Developments
- 4.9 Sanofi Aventis
- 4.9.1 Sanofi Aventis Company Information
- 4.9.2 Sanofi Aventis Business Overview
- 4.9.3 Sanofi Aventis 5-HT Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Sanofi Aventis 5-HT Receptor Antagonist Product Portfolio
- 4.9.5 Sanofi Aventis Recent Developments
- 4.10 Odyssey Pharmaceuticals
- 4.10.1 Odyssey Pharmaceuticals Company Information
- 4.10.2 Odyssey Pharmaceuticals Business Overview
- 4.10.3 Odyssey Pharmaceuticals 5-HT Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Odyssey Pharmaceuticals 5-HT Receptor Antagonist Product Portfolio
- 4.10.5 Odyssey Pharmaceuticals Recent Developments
- 4.11 Nu Pharm
- 4.11.1 Nu Pharm Company Information
- 4.11.2 Nu Pharm Business Overview
- 4.11.3 Nu Pharm 5-HT Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Nu Pharm 5-HT Receptor Antagonist Product Portfolio
- 4.11.5 Nu Pharm Recent Developments
- 4.12 Nidda Healthcare Holding Gmbh
- 4.12.1 Nidda Healthcare Holding Gmbh Company Information
- 4.12.2 Nidda Healthcare Holding Gmbh Business Overview
- 4.12.3 Nidda Healthcare Holding Gmbh 5-HT Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Nidda Healthcare Holding Gmbh 5-HT Receptor Antagonist Product Portfolio
- 4.12.5 Nidda Healthcare Holding Gmbh Recent Developments
- 4.13 Neuraxpharm Arzneimittel
- 4.13.1 Neuraxpharm Arzneimittel Company Information
- 4.13.2 Neuraxpharm Arzneimittel Business Overview
- 4.13.3 Neuraxpharm Arzneimittel 5-HT Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Neuraxpharm Arzneimittel 5-HT Receptor Antagonist Product Portfolio
- 4.13.5 Neuraxpharm Arzneimittel Recent Developments
- 4.14 Famar
- 4.14.1 Famar Company Information
- 4.14.2 Famar Business Overview
- 4.14.3 Famar 5-HT Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Famar 5-HT Receptor Antagonist Product Portfolio
- 4.14.5 Famar Recent Developments
- 4.15 Aspen Pharmacare
- 4.15.1 Aspen Pharmacare Company Information
- 4.15.2 Aspen Pharmacare Business Overview
- 4.15.3 Aspen Pharmacare 5-HT Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Aspen Pharmacare 5-HT Receptor Antagonist Product Portfolio
- 4.15.5 Aspen Pharmacare Recent Developments
- 4.16 Aristo Pharma
- 4.16.1 Aristo Pharma Company Information
- 4.16.2 Aristo Pharma Business Overview
- 4.16.3 Aristo Pharma 5-HT Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Aristo Pharma 5-HT Receptor Antagonist Product Portfolio
- 4.16.5 Aristo Pharma Recent Developments
- 4.17 Apotex
- 4.17.1 Apotex Company Information
- 4.17.2 Apotex Business Overview
- 4.17.3 Apotex 5-HT Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 Apotex 5-HT Receptor Antagonist Product Portfolio
- 4.17.5 Apotex Recent Developments
- 4.18 Ahaan Healthcare
- 4.18.1 Ahaan Healthcare Company Information
- 4.18.2 Ahaan Healthcare Business Overview
- 4.18.3 Ahaan Healthcare 5-HT Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.18.4 Ahaan Healthcare 5-HT Receptor Antagonist Product Portfolio
- 4.18.5 Ahaan Healthcare Recent Developments
- 4.19 Advanz Pharma
- 4.19.1 Advanz Pharma Company Information
- 4.19.2 Advanz Pharma Business Overview
- 4.19.3 Advanz Pharma 5-HT Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.19.4 Advanz Pharma 5-HT Receptor Antagonist Product Portfolio
- 4.19.5 Advanz Pharma Recent Developments
- 4.20 Abz-Pharma
- 4.20.1 Abz-Pharma Company Information
- 4.20.2 Abz-Pharma Business Overview
- 4.20.3 Abz-Pharma 5-HT Receptor Antagonist Sales, Revenue and Gross Margin (2021-2026)
- 4.20.4 Abz-Pharma 5-HT Receptor Antagonist Product Portfolio
- 4.20.5 Abz-Pharma Recent Developments
5 Global 5-HT Receptor Antagonist Market Scenario by Region
- 5.1 Global 5-HT Receptor Antagonist Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global 5-HT Receptor Antagonist Sales by Region: 2021-2032
- 5.2.1 Global 5-HT Receptor Antagonist Sales by Region: 2021-2026
- 5.2.2 Global 5-HT Receptor Antagonist Sales by Region: 2027-2032
- 5.3 Global 5-HT Receptor Antagonist Revenue by Region: 2021-2032
- 5.3.1 Global 5-HT Receptor Antagonist Revenue by Region: 2021-2026
- 5.3.2 Global 5-HT Receptor Antagonist Revenue by Region: 2027-2032
- 5.4 North America 5-HT Receptor Antagonist Market Facts & Figures by Country
- 5.4.1 North America 5-HT Receptor Antagonist Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America 5-HT Receptor Antagonist Sales by Country (2021-2032)
- 5.4.3 North America 5-HT Receptor Antagonist Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe 5-HT Receptor Antagonist Market Facts & Figures by Country
- 5.5.1 Europe 5-HT Receptor Antagonist Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe 5-HT Receptor Antagonist Sales by Country (2021-2032)
- 5.5.3 Europe 5-HT Receptor Antagonist Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific 5-HT Receptor Antagonist Market Facts & Figures by Country
- 5.6.1 Asia Pacific 5-HT Receptor Antagonist Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific 5-HT Receptor Antagonist Sales by Country (2021-2032)
- 5.6.3 Asia Pacific 5-HT Receptor Antagonist Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America 5-HT Receptor Antagonist Market Facts & Figures by Country
- 5.7.1 South America 5-HT Receptor Antagonist Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America 5-HT Receptor Antagonist Sales by Country (2021-2032)
- 5.7.3 South America 5-HT Receptor Antagonist Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa 5-HT Receptor Antagonist Market Facts & Figures by Country
- 5.8.1 Middle East and Africa 5-HT Receptor Antagonist Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa 5-HT Receptor Antagonist Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa 5-HT Receptor Antagonist Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global 5-HT Receptor Antagonist Sales by Type (2021-2032)
- 6.1.1 Global 5-HT Receptor Antagonist Sales by Type (2021-2032) & (k units)
- 6.1.2 Global 5-HT Receptor Antagonist Sales Market Share by Type (2021-2032)
- 6.2 Global 5-HT Receptor Antagonist Revenue by Type (2021-2032)
- 6.2.1 Global 5-HT Receptor Antagonist Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global 5-HT Receptor Antagonist Revenue Market Share by Type (2021-2032)
- 6.3 Global 5-HT Receptor Antagonist Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global 5-HT Receptor Antagonist Sales by Application (2021-2032)
- 7.1.1 Global 5-HT Receptor Antagonist Sales by Application (2021-2032) & (k units)
- 7.1.2 Global 5-HT Receptor Antagonist Sales Market Share by Application (2021-2032)
- 7.2 Global 5-HT Receptor Antagonist Revenue by Application (2021-2032)
- 7.2.1 Global 5-HT Receptor Antagonist Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global 5-HT Receptor Antagonist Revenue Market Share by Application (2021-2032)
- 7.3 Global 5-HT Receptor Antagonist Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 5-HT Receptor Antagonist Value Chain Analysis
- 8.1.1 5-HT Receptor Antagonist Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 5-HT Receptor Antagonist Production Mode & Process
- 8.2 5-HT Receptor Antagonist Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 5-HT Receptor Antagonist Distributors
- 8.2.3 5-HT Receptor Antagonist Customers
9 Global 5-HT Receptor Antagonist Analyzing Market Dynamics
- 9.1 5-HT Receptor Antagonist Industry Trends
- 9.2 5-HT Receptor Antagonist Industry Drivers
- 9.3 5-HT Receptor Antagonist Industry Opportunities and Challenges
- 9.4 5-HT Receptor Antagonist Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst